Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > ACADEMIA
ACADEMIA
- JSN Revises CKD Guidelines; Changes Severity Classifications
May 31, 2012
- Serious ADR for Abatacept shows 2.4%, Lower Than Other RA Drugs: All-Case PMS Interim Analysis
May 7, 2012
- St. Marianna University School of Medicine Hospital to Introduce CDTM, Protocols for Pharmacists to Determine Prescriptions
April 27, 2012
- Remission Rate Equal in Antirheumatic Drugs, Anti-TNF Drugs in JaSTAR’s Interim Analysis
April 26, 2012
- Adoption of NGSP Values for HbA1c Measurement to “Enable Japan’s Leadership in Clinical Trials”: Prof. Kadowaki
April 10, 2012
- Generic Name Prescriptions Rapidly Rise on New Premium, Tokyo Pharmaceutical Association Issues Warning
April 9, 2012
- Industry-Academia-Government Research Group to Build Adjuvant Database, Support Next-Generation Vaccine Development
March 29, 2012
- Prof. Nakamura Renews Call for Establishment of Drug Discovery Support Organization
March 9, 2012
- Insulin Stockpiles Insufficient at Medical Facilities in Disaster-Hit Areas: JDS Survey
March 6, 2012
- Osaka Medical Center President Hori says “Once-Daily Xarelto is Easy to Take”
February 27, 2012
- JAS 2012 GL Calls for Consideration of Medication for Primary Prevention in Patients with LDL-C Levels Over 180 mg/dL
February 7, 2012
- Demand for Celecox Expected to Increase for Acute Pain Relief: Prof. Ishiguro
January 26, 2012
- Manufacturers Report on Patient Benefits of Oral RI Drugs
January 24, 2012
- JDS to Use NGPS Score for HbA1c in Clinical Practices from April
January 23, 2012
- A New Industry Could Be Created in the Field of Pre-Symptomatic Medical Intervention: Kyoto Univ. Prof. Kawakami
January 16, 2012
- Specialists Debate Pro, Cons of Early Pharm. Intervention in Dementia
January 16, 2012
- MD Studies Could Increase Development Success Rate to 30%: Prof. Sugiyama
December 20, 2011
- Kyushu University Professor Egashira Says Suppression of Vascular Inflammation Can Be Target for Development
November 30, 2011
- JDA Requests Additional Indication of Pustular Psoriasis for Humira
November 22, 2011
- JSMO Issues 33 Development Requests for Unapproved Drugs, Indications
November 22, 2011
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…